JAYDEEP SINHA

Mr. JAYDEEP SINHA


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMurugaiah A. M. Subbaiah
Murugaiah A. M. Subbaiah
SMSandhya Mandlekar
Sandhya Mandlekar
SDSridhar Desikan
Sridhar Desikan
TRThangeswaran Ramar
Thangeswaran Ramar
LSLakshumanan Subramani
Lakshumanan Subramani
NMNicholas A. Meanwell
Nicholas A. Meanwell

18 May 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JGJacqueline G. Gerhart
Jacqueline G. Gerhart
FCFernando O. Carreño
Fernando O. Carreño
MLMatthew Shane Loop
Matthew Shane Loop
CLCraig R. Lee
Craig R. Lee
AEAndrea Edginton
Andrea Edginton
TCthe Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Dosing guidance for children with obesity is often unknown despite the fact that nearly 20% of US children are classified as obese. Enoxaparin, a commonly prescribed low‐molecular‐weight heparin, is dosed based on body weight irrespective of obesity status to achieve maximum concentration within a narrow therapeutic or prophylactic target range. However, whether children with and without obesity experience equivalent enoxaparin exposure remains unclear. To address this clinical question, 2,825 anti–activated factor X (anti‐Xa) surrogate concentrations were collected from the electronic health records of 596 children, including those with obesity. Using linear mixed‐effects regression models, we observed that 4‐hour anti‐Xa concentrations were statistically significantly different in children with and without obesity, even for children with the same absolute dose (P = 0.004). To further mechanistically explore obesity‐associated differences in anti‐Xa concentration, a pediatric physiologically‐based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity. This PBPK model incorporated binding of enoxaparin to antithrombin to form anti‐Xa and elimination via heparinase‐mediated metabolism and glomerular filtration. Following scaling, the PBPK model predicted real‐world pediatric concentrations well, with an average fold error (standard deviation of the fold error) of 0.82 (0.23) and 0.87 (0.26) in children with and without obesity, respectively. PBPK model simulations revealed that children with obesity have at most 20% higher 4‐hour anti‐Xa concentrations under recommended, total body weight–based dosing compared to children without obesity owing to reduced weight‐normalized clearance. Enoxaparin exposure was better matched across age groups and obesity status using fat‐free mass weight‐based dosing.

29 June 2021 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
DGDaniel Gonzalez
Daniel Gonzalez
JSJAYDEEP SINHA
JAYDEEP SINHA
Hospitalized pediatric patients and those with complex or chronic conditions treated on an outpatient basis are commonly prescribed multiple drugs, resulting in increased risk for drug‐drug interactions (DDIs). Although dedicated DDI evaluations are routinely performed in healthy adult volunteers during drug development, they are rarely performed in pediatric patients because of ethical, logistical, and methodological challenges. In the absence of pediatric DDI evaluations, adult DDI data are often extrapolated to pediatric patients. However, the magnitude of a DDI in pediatric patients may differ from adults because of age‐dependent physiological changes that can impact drug disposition or response and because of other factors related to the drug (eg, dose, formulation) and the patient population (eg, disease state, obesity). Therefore, the DDI magnitude needs to be assessed in children separately from adults, although a lack of clinical DDI data in pediatric populations makes this evaluation challenging. As a result, pediatric DDI assessment relies on the predictive performance of the pharmacometric approaches used, such as population and physiologically based pharmacokinetic modeling. Therefore, careful consideration needs to be given to adequately account for the age‐dependent physiological changes in these models to build high confidence for such untested DDI scenarios. This review article summarizes the key considerations related to the drug, patient population, and methodology, and how they can impact DDI evaluation in the pediatric population.

12 January 2018 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
JSJAYDEEP SINHA
JAYDEEP SINHA
SDStephen B. Duffull
Stephen B. Duffull
HAHesham S. Al-Sallami
Hesham S. Al-Sallami

27 April 2018 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
JSJAYDEEP SINHA
JAYDEEP SINHA
HAHesham S. Al-Sallami
Hesham S. Al-Sallami
SDStephen B. Duffull
Stephen B. Duffull

31 March 2015 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
PDF file
VHVinay K. Holenarsipur
Vinay K. Holenarsipur
NGNilesh Gaud
Nilesh Gaud
JSJAYDEEP SINHA
JAYDEEP SINHA
SSSankara Sivaprasad
Sankara Sivaprasad
PBPriyadeep Bhutani
Priyadeep Bhutani
SMSandhya Mandlekar
Sandhya Mandlekar